Progress and future in living donor liver transplantation.

Kōichi TanakaThe Keio Journal of Medicine 2003 · DOI

Abstract

Living donor liver transplantation (LDLT) is a new modality that has been developed to overcome the shortage of available cadaveric livers for transplantation. This modality now covers a wide range from newborn to advanced age. However, the evolution has revealed many unresolved problems such as liver anatomy, physiology, and immunology as well as social and psychological controversies. I'd like to discuss the progress in and future of LDLT.

Introduction

Living donor liver transplantation (LDLT) emerged as a surgical innovation driven by the critical shortage of cadaveric organs. In regions like Japan, this necessity was historically amplified by the late legal and social acceptance of "brain death," which made traditional deceased-donor transplants exceptionally rare. Beyond supply issues, LDLT presented unique physiological and technical hurdles, specifically the challenge of using only a portion of a liver. Surgeons had to ensure the partial graft was sufficient to support the recipient—avoiding "small-for-size syndrome"—while ensuring the donor's remaining liver could safely regenerate.

Clinical and Surgical Innovations

The evolution of LDLT from a niche pediatric procedure to a viable adult treatment relied on several key breakthroughs, many pioneered at Kyoto University:

  • Microsurgical Artery Reconstruction: To address hepatic artery thrombosis, a frequent cause of graft failure, the introduction of microsurgery reduced complication rates from approximately 20% to just 1.5%.
  • Right Lobe Grafting: Introduced in 1998, this technique allowed for larger grafts (roughly 60% of liver volume), making transplantation feasible for larger adult recipients who could not be sustained by smaller left-lobe segments.
  • Graft Size Matching (GRWR): The Graft Weight / Recipient Body Weight (GRWR) ratio became a standard metric, establishing a 0.8% threshold as the minimum necessary for recipient survival.
  • ABO-Incompatible Protocols: Specialized infusion therapies via the portal vein and hepatic artery were developed to allow successful transplants between mismatched blood types, achieving one-year survival rates of 86% in adults.
  • Immunosuppression Weaning: Novel protocols aimed at "immunological tolerance" allowed some patients to gradually transition off long-term drug dependency, with some achieving complete withdrawal.

Growth and Outcomes

The program at Kyoto University serves as a primary case study for the global expansion of LDLT. Between 1990 and October 2002, the institute performed 850 cases, showing a steady increase in both pediatric and adult procedures as the technology matured.

Annual and cumulative LDLT cases at Kyoto University (1990-2002) showing the shift from pediatric to adult cases.

Survival and Physiological Insights

The success of LDLT is underpinned by the liver's remarkable regenerative capacity. A partial graft grows to full size in the recipient, while the donor's remaining liver returns to near-original volume. Clinical data reflects this success, with cumulative survival rates reaching approximately 85% in children and 70% in adults.

Patient and graft survival rates for pediatric and adult recipients over time.

One of the most significant findings was the 0.8% GRWR threshold; grafts below this size often lead to poor synthetic function and cholestasis. Furthermore, the discovery that some patients could maintain graft function after withdrawing immunosuppression suggests the liver may have unique tolerogenic properties compared to other organs.

Challenges and Future Directions

Despite significant progress, several challenges remain:

  • Donor Safety: Donor risk remains the paramount ethical concern. While complication rates are monitored closely, the goal remains zero mortality for these healthy volunteers.
  • Hepatitis C Recurrence: The rapid viral replication during the liver's regenerative phase can lead to accelerated graft failure in HCV patients.
  • Small-for-Size Syndrome: Further research is needed to understand how graft quality (e.g., donor age or fatty liver) interacts with recipient metabolic demands beyond simple weight ratios.

The future of liver transplantation involves a balanced integration of living donor programs with the continued development of cadaveric systems to provide the best possible outcomes for all patients.

Summary updated

Abstract

Living donor liver transplantation (LDLT) is a new modality that has been developed to overcome the shortage of available cadaveric livers for transplan tation. This modality now covers a wide range from newborn to advanced age. However, the evolution has revealed many unresolved problems such as liver anatomy, physiology, and immunology as well as social and psychological controversies. I'd like to discuss the progress in and future of LDLT.
BibTeX
@article{tanaka2003progress,
  author = {Kōichi Tanaka},
  title = {{Progress and future in living donor liver transplantation.}},
  journal = {The Keio Journal of Medicine},
  year = {2003},
  doi = {10.2302/kjm.52.73},
}
Figure